Last updated: September 7, 2026
REL-1017, also known as esmethadone or d-methadone, remains an investigational oral treatment for major depressive disorder (MDD). Relmada Therapeutics has not received FDA approval, and REL-1017 has no Orange Book listing or commercial revenue. The investment case depends on whether Relmada can overcome mixed Phase 3 results, define an approvable patient population, and finance additional clinical development. Based on the public development record, REL-1017 has a materially higher regulatory and commercial risk profile than approved rapid-acting antidepressants such as Auvelity and Spravato.
What is the current development status of REL-1017?
REL-1017 is an oral, once-daily formulation of esmethadone hydrochloride. The compound is designed to act primarily as an N-methyl-D-aspartate, or NMDA, receptor antagonist while limiting the opioid activity associated with racemic methadone. Relmada has developed REL-1017 for adjunctive treatment of MDD, particularly in patients who do not respond adequately to standard antidepressants.
The program has advanced through Phase 3 clinical testing. Public company disclosures indicate that the pivotal program produced mixed results and did not establish a clear regulatory path to approval. The clinical development strategy has therefore remained dependent on additional analysis, regulatory interaction, financing, and possible further trials rather than an immediate commercial launch (Relmada Therapeutics, 2024a; U.S. National Library of Medicine, n.d.).
| Item |
Current assessment |
| Drug candidate |
REL-1017 |
| Active ingredient |
Esmethadone hydrochloride, also called d-methadone |
| Developer |
Relmada Therapeutics, Inc. |
| Route |
Oral |
| Intended use |
Adjunctive treatment of major depressive disorder |
| FDA approval |
None |
| FDA exclusivity |
None |
| Orange Book listing |
None |
| Commercial sales |
None |
| Development stage |
Phase 3 completed or substantially advanced, with regulatory uncertainty |
| Primary risk |
Need for a convincing efficacy and safety package after mixed pivotal results |
What Phase 3 trials evaluated REL-1017?
Relmada’s pivotal program was known as the Reliance program. The studies evaluated REL-1017 as an adjunct to ongoing antidepressant therapy in adults with MDD who had an inadequate response to treatment.
Reliance clinical program
The principal efficacy measure was change in depressive symptoms, generally assessed with the Montgomery-Åsberg Depression Rating Scale, or MADRS. The program tested whether REL-1017 could produce a rapid and clinically meaningful reduction in depressive symptoms compared with placebo.
The development record has several commercial implications:
- REL-1017 was not positioned as a first-line replacement for generic antidepressants.
- The initial target market was treatment-resistant or inadequately responsive MDD.
- The drug’s value proposition depended on rapid symptom improvement without the administration burden of intranasal or intravenous ketamine products.
- Mixed pivotal efficacy results reduce the probability that the compound can reach approval without further evidence.
Relmada’s filings have described clinical, regulatory, financing, and operational risks associated with the program. The company has also reported that development decisions depend on available capital and discussions with regulators (Relmada Therapeutics, 2024a).
When could REL-1017 reach the market?
REL-1017 does not have an established FDA approval date. A commercial launch would require a regulatory filing accepted by the FDA, a positive review, manufacturing validation, labeling agreement, and commercial readiness.
| Milestone |
Status |
| Phase 3 clinical development |
Completed or substantially advanced |
| New Drug Application |
No public approval |
| FDA approval |
Not granted |
| Launch date |
Not established |
| Earliest practical launch scenario |
Dependent on additional clinical and regulatory work |
A successful launch before 2027 would have required a substantially de-risked clinical package and rapid regulatory execution. Given the lack of approval and the reported mixed efficacy record, a later launch scenario is more credible. If additional Phase 3 work is required, a U.S. launch could move several years beyond the original development timetable.
What is the FDA regulatory status and Orange Book status of REL-1017?
The FDA has not approved REL-1017 for MDD or another indication. As a result, the product has no FDA-recognized reference-listed drug status, no Orange Book patents, and no regulatory exclusivity period.
Orange Book and exclusivity
| Regulatory category |
REL-1017 status |
| Approved drug |
No |
| Reference-listed drug |
No |
| Orange Book listing |
No |
| New Chemical Entity exclusivity |
Not awarded |
| Orphan-drug exclusivity |
No public award for the MDD program |
| Pediatric exclusivity |
None |
| Qualified infectious disease exclusivity |
Not applicable |
Paragraph IV litigation is not currently a central risk because no approved REL-1017 product has been listed in the Orange Book. If approved, Relmada could seek patent protection for composition, formulation, method of treatment, and manufacturing claims. Generic applicants would then be able to challenge listed patents through an abbreviated new drug application and Paragraph IV certification.
What patents protect REL-1017?
The public commercial record does not establish a single, verified patent expiration date that can be treated as the definitive loss-of-exclusivity date for REL-1017. The potential patent estate is likely to include several claim categories:
Composition and salt patents
Composition claims can cover esmethadone, specific salt forms, crystalline forms, stereochemical purity, or pharmaceutical compositions containing the active ingredient. These claims provide the strongest protection if they remain valid and cover the commercial product.
Method-of-use patents
Relmada has pursued claims directed to treatment of depression and related psychiatric conditions. Method-of-use claims can protect adjunctive treatment, dosing schedules, rapid antidepressant response, and specific patient populations. Their value depends on claim scope, enforceability, and whether a generic label can avoid the patented indication.
Formulation patents
Formulation claims may cover oral tablets, modified-release systems, stability characteristics, excipient combinations, or dosage strengths. These patents can delay direct substitution but often leave room for alternative formulations if the active ingredient itself is no longer protected.
Manufacturing and process patents
Manufacturing claims may protect stereochemical enrichment, purification, crystallization, or production of a specific salt or solid-state form. Such claims can raise development costs for competitors but rarely provide the same commercial barrier as a broad composition patent.
No confirmed Orange Book patent number or final patent-term schedule should be used to model REL-1017’s loss of exclusivity before approval and listing. The relevant patent family would need to be evaluated across the United States, Europe, Japan, and other major markets.
How strong is the REL-1017 patent estate?
The patent estate appears strategically useful but commercially unproven. Patent strength depends less on the number of filings than on whether the surviving claims cover the actual approved product and its principal use.
| Patent category |
Potential value |
Main vulnerability |
| Active ingredient or composition |
High |
Validity, prior art, claim breadth |
| Specific salt or solid form |
Medium to high |
Alternative solid forms |
| MDD method of use |
Medium |
Label carve-outs and off-label prescribing |
| Adjunctive dosing regimen |
Medium |
Design-around dosing |
| Oral formulation |
Medium |
Competing formulations |
| Manufacturing process |
Low to medium |
Alternative processes |
The patent position is weaker if protection relies mainly on narrow formulation or method claims. The position is stronger if Relmada holds an unexpired, enforceable composition patent covering esmethadone in the marketed form.
Which companies compete with REL-1017?
REL-1017 would compete in a rapidly expanding market for treatment-resistant depression, rapid-acting antidepressants, and adjunctive therapy.
| Product |
Company |
Mechanism or platform |
Commercial status |
| Auvelity |
Axsome Therapeutics |
Dextromethorphan plus bupropion |
FDA-approved for MDD |
| Spravato |
Johnson & Johnson |
Esketamine nasal spray |
FDA-approved for treatment-resistant depression and related uses |
| Generic aripiprazole, brexpiprazole, quetiapine |
Multiple manufacturers |
Adjunctive or atypical antipsychotic therapy |
Approved, largely generic |
| Trintellix |
Takeda and Lundbeck |
Vortioxetine |
FDA-approved antidepressant |
| Zoloft, Lexapro, Prozac and others |
Multiple manufacturers |
SSRIs and related antidepressants |
Generic or branded |
| Ketamine clinics |
Multiple providers |
Racemic ketamine |
Off-label, not FDA-approved for MDD |
REL-1017’s proposed advantages are oral administration, a potentially rapid onset of action, and avoidance of the controlled-administration infrastructure associated with Spravato. Its disadvantages include an unproven regulatory pathway, clinical differentiation risk, and competition from an approved oral rapid-acting product, Auvelity.
What generic entry risks exist for REL-1017?
Generic entry would likely occur in stages rather than through a single event.
First, an ANDA applicant could challenge listed composition patents through Paragraph IV certification. Second, generic manufacturers could seek approval for unprotected strengths, formulations, or indications. Third, a generic could pursue a label that omits patented uses while relying on widespread off-label prescribing.
The principal entry scenarios are:
- Approval with broad composition protection, followed by delayed generic entry.
- Approval with narrow method and formulation patents, allowing earlier design-around competition.
- Approval without commercially meaningful patent protection, creating rapid price pressure.
- No approval, in which case generic entry is irrelevant but the development investment is impaired.
Controlled-substance regulation may create additional manufacturing and distribution requirements, although those controls would not replace patent protection.
Does REL-1017 have biosimilar risk?
REL-1017 has no biosimilar risk because it is a small-molecule drug candidate rather than a biologic. If approved, the principal competitive threat would come from small-molecule generics, alternative formulations, and competing antidepressant products.
Has Relmada signed licensing deals for REL-1017?
Relmada has retained primary control of REL-1017 in its public corporate disclosures. No major global commercialization transaction comparable to a large-pharma co-development or regional licensing deal has been publicly established as the basis for the asset’s commercial plan.
The absence of a major licensing partner has two effects. Relmada retains more economic upside if the program succeeds, but it also bears the cost of late-stage development, regulatory execution, manufacturing, and commercialization. A partnership could provide validation and capital, but the mixed clinical record would likely reduce negotiating leverage.
What is the market size and revenue projection for REL-1017?
The addressable market is large in patient numbers but difficult to monetize because generic antidepressants dominate treatment. The most credible initial segment is adults with MDD who have failed one or more antidepressants and need a rapid oral adjunctive option.
A scenario-based U.S. projection is more appropriate than a single-point forecast.
| Scenario |
Assumption |
Peak annual U.S. sales |
| Low |
Narrow label, modest efficacy differentiation, heavy payer controls |
$100 million to $300 million |
| Base |
Approval for adjunctive MDD, differentiated onset, moderate adoption |
$400 million to $800 million |
| High |
Broad use in treatment-resistant MDD and strong commercial access |
$1.0 billion to $1.5 billion |
These figures are not company guidance. They assume annual net pricing of approximately $8,000 to $12,000, a treated population of roughly 50,000 to 150,000 patients at peak penetration, and meaningful payer coverage. Auvelity’s presence limits the pricing and uptake opportunity, while Spravato’s administration burden creates a possible opening for an oral product.
A risk-adjusted valuation would be materially lower. With no approval and a pivotal efficacy record that has not produced a clear launch path, a probability of technical and regulatory success in the low-teens range would be more defensible than the probability assigned to an already approved late-stage product. On that basis, a $400 million to $800 million peak-sales opportunity could translate into roughly $50 million to $120 million of risk-adjusted peak revenue before discounting for time, development costs, dilution, and future competition.
What patent litigation or settlement agreements affect REL-1017?
No major Orange Book patent litigation or Paragraph IV settlement is associated with REL-1017 because the product has not been approved and listed. No generic settlement agreement is a material current valuation input.
Future disputes could involve:
- Validity of esmethadone composition claims.
- Infringement of formulation or salt patents.
- Carve-out labels for patented MDD uses.
- Regulatory exclusivity versus patent-term protection.
- Manufacturing claims involving stereochemical purity or crystalline form.
How does REL-1017 compare with Auvelity and Spravato?
| Factor |
REL-1017 |
Auvelity |
Spravato |
| FDA status |
Investigational |
Approved |
Approved |
| Administration |
Oral, once daily in development |
Oral |
Intranasal under supervision |
| Core mechanism |
NMDA antagonism |
Dextromethorphan plus bupropion |
Esketamine |
| Rapid-acting positioning |
Intended |
Yes |
Yes |
| Administration burden |
Potentially low |
Low |
High |
| Clinical certainty |
Unresolved |
Commercial and regulatory precedent |
Commercial and regulatory precedent |
| Generic risk |
Future, if approved |
Future patent and generic risk |
Patent, exclusivity, and biosimilar risk not applicable |
| Main differentiation |
Oral NMDA approach and potential tolerability |
Approved oral rapid-acting treatment |
Established rapid-acting treatment for resistant depression |
REL-1017 could occupy a clinically attractive position if it demonstrates rapid efficacy, acceptable tolerability, low abuse liability, and convenient oral dosing. The current evidence does not yet establish that differentiation.
Key Takeaways
- REL-1017 is an investigational oral esmethadone product for adjunctive treatment of MDD.
- Relmada has not obtained FDA approval, Orange Book listing, or commercial revenue.
- The Phase 3 program produced a development record that has not established a clear approval path.
- No confirmed loss-of-exclusivity date should be used until the applicable patent families and FDA listing are verified.
- REL-1017 has no biosimilar risk, but it would face generic small-molecule competition if approved.
- Auvelity and Spravato are the most relevant approved rapid-acting comparators.
- Unadjusted peak U.S. sales could range from approximately $100 million to $1.5 billion, depending on label, efficacy, payer coverage, and differentiation.
- A risk-adjusted commercial valuation is substantially lower because the product remains unapproved and the pivotal clinical package is unresolved.
FAQs About REL-1017
Is REL-1017 the same as methadone?
REL-1017 is esmethadone, also called d-methadone. It is the dextrorotatory enantiomer of methadone and is being developed separately from racemic methadone products used for opioid-use disorder and pain.
Is REL-1017 approved for depression?
No. The FDA has not approved REL-1017 for MDD, treatment-resistant depression, or another indication.
Is REL-1017 a controlled substance?
REL-1017 is chemically related to methadone, so controlled-substance and abuse-liability issues are important regulatory considerations. Its final scheduling treatment would depend on FDA and Drug Enforcement Administration determinations.
Could REL-1017 compete with ketamine?
Yes. Its intended competitive position is a convenient oral NMDA-based treatment that could avoid the clinic-based administration required for many ketamine and esketamine regimens. Approval would require evidence that its efficacy and safety justify that positioning.
What would most improve the REL-1017 investment case?
The largest value drivers would be a positive regulatory pathway, reproducible Phase 3 efficacy, a clear safety profile, adequate financing, and patent claims that cover the commercial product through the period of peak adoption.
References
-
Relmada Therapeutics, Inc. (2024a). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K. U.S. Securities and Exchange Commission.
-
Relmada Therapeutics, Inc. (2024b). Corporate presentations and clinical development updates for REL-1017. Relmada Therapeutics.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Studies of REL-1017 in major depressive disorder. National Institutes of Health.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
